<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02696564</url>
  </required_header>
  <id_info>
    <org_study_id>U01HL128951</org_study_id>
    <nct_id>NCT02696564</nct_id>
  </id_info>
  <brief_title>Losartan Effects on Emphysema Progression</brief_title>
  <acronym>LEEP</acronym>
  <official_title>Losartan Effects on Emphysema Progression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, parallel, placebo controlled trial to evaluate the effect of 100mg/day losartan
      on the progression of emphysema as measured by quantitative HRCT compared to placebo
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pragmatic trial designed to test if a treatment, losartan, may decrease the
      progression of Chronic Obstructive Pulmonary Disease (COPD). Losartan is an angiotensin
      receptor blocking agent, commonly used as an antihypertensive agent, which has been shown to
      alter cardiac remodeling after myocardial infarction and renovascular remodeling in
      diabetes-mellitus. In this trial participants with mild to severe COPD, with Computed
      Tomography (CT) evidence of emphysema (5-35% of voxels with &lt; -950 Hounsfield Units), will be
      randomly assigned to receive 100mg/day of losartan or placebo for 48 weeks. The primary
      outcome measure will be the rate of progression of emphysema, quantified as the percent of
      lung voxels with a density less than -950 HU as measured by High Resolution CT (HRCT, from
      baseline to 48 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 23, 2017</start_date>
  <completion_date type="Anticipated">January 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in mean pct950</measure>
    <time_frame>48 weeks</time_frame>
    <description>change in percentage of voxels with density less than -950 Hounsfield Units</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Emphysema</condition>
  <arm_group>
    <arm_group_label>Losartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>At randomization participants will start with a dose of 50mg (one capsule) once a day for 2 weeks. If this dose is well tolerated and systolic BP is &gt;90 mm Hg and diastolic BP is &gt; 60 mm Hg, the dose will be increased to 100 mg (2 capsules) once a day for the remaining 46 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>At randomization participants will start with a dose of one capsule (inactive) once a day for 2 weeks. After two weeks, if systolic BP is &gt;90 mm Hg and diastolic BP is &gt; 60 mm Hg, the dose will be increased to 2 capsules once a day for the remaining 46 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>50mg once per day for two weeks,followed by 100mg once per day for 46 weeks if increased dose tolerated</description>
    <arm_group_label>Losartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>one capsule per day for two weeks, followed by two capsules per day for 46 weeks</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mild to severe COPD: Ratio of forced expiratory volume in 1 second (FEV1)/forced vital
             capacity (FVC) less than or equal to 0.70, FEV1 30-70% of predicted

          -  Current or former smoker

          -  HRCT scan with 5-35% of voxels with density less than -950 Hounsfield Units (HU)

          -  Ability to understand and willingness to sign consent documents

        Exclusion Criteria:

          -  Current therapy with angiotensin converting enzyme (ACE) inhibitor or angiotensin
             receptor blocker (ARB)

          -  Known intolerance to ACE inhibitor or ARB

          -  History of angioedema

          -  Conventional indication for ACE inhibitor or ARB (e.g., history of myocardial
             infarction, known cardiomyopathy)

          -  Renal insufficiency (GFR &lt;30 mL/min by Cockcroft-Gault calculation)

          -  Current regular use of NSAIDs defined as daily use 5 or more days of the week for more
             than one month

          -  Potassium supplementation or serum potassium level of 5.0 milliequivalents (mEq)/dL or
             higher at V1

          -  Current use of a potassium sparing diuretic

          -  COPD exacerbation requiring treatment within 6 weeks at V1

          -  Chronic systemic corticosteroid use of more than 10mg/day of prednisone

          -  Chronic oxygen use at more than 2 L/min nasal cannula at rest or clinical evidence of
             cor pulmonale

          -  Untreated arterial hypertension (systolic blood pressure greater than140 mm Hg,
             diastolic blood pressure greater than 90 mm Hg)

          -  Blood pressure less than 90 mm Hg systolic or 60 mm Hg diastolic while standing or
             sitting

          -  Known unilateral or bilateral renal artery stenosis higher than 70%

          -  Previous lung resection surgery

          -  Evidence of interstitial, occupational or chronic infectious lung disease

          -  Changes to chest that preclude adequate HRCT imaging (e.g. Metallic objects in the
             chest such as shrapnel or pacemaker leads)

          -  For women of child bearing potential, positive pregnancy test or unwillingness to use
             two methods of birth control or abstinence for the duration of the study

          -  Major chronic illnesses which in the judgment of the study physician would interfere
             with participation in the study e.g. including but not limited to: cardiac, renal,
             hepatic (LFTs more than 2.5x normal upper limit), neurological, psychiatric, endocrine
             or neoplastic diseases, uncontrolled diabetes, uncontrolled HIV infection or other
             immune system disorder, hyperthyroidism, seizure disorders, non-skin cancer, rheumatic
             diseases

          -  Failure to keep screening appointments or other indicators of non-adherence

          -  Inability to be contacted by telephone

          -  Intention to leave area within 12 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Wise, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Janet Holbrook, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University Bloomberg School of Public Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne Casper, MA</last_name>
    <phone>443-287-2744</phone>
    <email>ashankl1@jhu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexis Rea</last_name>
    <email>area5@jhu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Necole Harris</last_name>
      <phone>205-934-9240</phone>
      <email>nharris@uabmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Provencio-Dean</last_name>
      <phone>520-626-6231</phone>
      <email>nataliep@email.arizona.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California at San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amber Martineau</last_name>
      <phone>619-471-0817</phone>
      <email>ajm002@ucsd.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California at San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julian Silva</last_name>
      <email>julian.silva@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Jewish Medical and Research Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juno Pak</last_name>
      <phone>303-398-1443</phone>
      <email>pakj@njhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Florida College of Medicine</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minal Patel</last_name>
      <phone>904-244-1106</phone>
      <email>minal.patel@jax.ufl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine R Smith</last_name>
      <phone>813-631-4024</phone>
      <email>catherinesmith@health.usf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Illinois Consortium</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenny Hixon</last_name>
      <phone>312-926-0975</phone>
      <email>j-franzen@northwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Vincent Hospital and Health Care Center, Inc.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debra Weiss</last_name>
      <phone>317-338-8030</phone>
      <email>dweiss@stvincent.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-5360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheryl Majors</last_name>
      <phone>734-764-7388</phone>
      <email>cmajors@med.umich.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Louis Asthma Clinical Research Center - Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaime Tarsi</last_name>
      <phone>314-747-3074</phone>
      <email>jtarsi@dom.wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Scheuerman</last_name>
      <phone>212-305-4675</phone>
      <email>ms4311@columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Foss</last_name>
      <phone>919-668-6530</phone>
      <email>catherine.foss@duke.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Temple University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francine McGonagle, BSN, RN</last_name>
      <phone>215-707-2682</phone>
      <email>Francine.McGonagle@tuhs.temple.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Bertrand</last_name>
      <phone>713-798-2681</phone>
      <email>laura.bertrand@bcm.tmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vermont Lung Center at The University of Vermont</name>
      <address>
        <city>Colchester</city>
        <state>Vermont</state>
        <zip>05466</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Burns</last_name>
      <phone>802-847-2103</phone>
      <email>stephanie.burns@vtmednet.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pacific Northwest Airways - VA Puget Sound Healthcare System</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ed Udris</last_name>
      <phone>206-764-2558</phone>
      <email>edmunds.udris@va.gov</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2016</study_first_submitted>
  <study_first_submitted_qc>February 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2016</study_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>emphysema</keyword>
  <keyword>HRCT</keyword>
  <keyword>losartan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emphysema</mesh_term>
    <mesh_term>Pulmonary Emphysema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>NHLBI Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC)</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

